Chinese Medicine scholars have succeeded in developing a novel targeted delivery system for CRISPR/Cas9 to achieve therapeutic genome editing of VEGFA in osteosarcoma (OS).
Chinese Medicine scholars have succeeded in developing a novel targeted delivery system for CRISPR/Cas9 to achieve therapeutic genome editing of VEGFA in osteosarcoma (OS).